阿奇霉素治疗小儿上呼吸道肺炎支原体感染临床效果观察

doi:10.3969/j.issn.1006-6233.2018.02.040

Abstract
Figure/Table
References
Related Citation (7)

Download: PDF (1314 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the clinical effect of azithromycin in the treatment of Mycoplasma pneumoniae infection in children with upper respiratory tract. Methods: 100 cases of upper respiratory tract mycoplasma pneumoniae infection in our hospital from October 2016 to July 2017 were randomly divided into two groups, azithromycin group receiving azithromycin and clarithromycin group receiving clarithromycin, The clinical indicators, the overall treatment effect, the related disease parameters and the adverse reactions of the two groups were compared. Results: The antipyretic time, the disappearance of cough, the disappearance of rales and the disappearance of wheeze in the azithromycin group were significantly lower than those in the clarithromycin group; the cure rate was significantly higher than that in the clarithromycin group; after treatment, the lymphocytes , IgA, IgE and IgG levels were significantly higher than the clarithromycin group, CRP and IL-4 levels were significantly lower than the clarithromycin group, there was a significant difference (P <0.01); two groups of children There was no significant difference in adverse reaction rate of all kinds of drugs (P> 0.05). Conclusion: azithromycin in children with upper respiratory tract infection Mycoplasma pneumoniae clinical effect is significant, higher safety, with reference.

Key words： Upper respiratory tract pneumonia Azithromycin Mycoplasma infection

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAI Qinwu
	YANG Zijiang
	WANG Changle

Cite this article:

CAI Qinwu,YANG Zijiang,WANG Changle. Clinical Observation of Azithromycin in treating Mycoplasma Pneumoniae Infection in Children with Upper Respiratory Tract[J]. HeBei Med, 2018, 24(2): 328-332.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.02.040 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I2/328

[1] 韦润锋.左氧氟沙星与阿奇霉素治疗支原体肺炎的疗效对比[J].实用临床医药杂志,2015,19(23):160~161.
[2] 席日升,刘海,李芙蓉.自拟中医方剂联合阿奇霉素治疗小儿衣原体肺炎34例[J].中国药业,2015(22):189~191.
[3] 胡亚美,江载芳,申昆玲,沈颖.诸福棠实用儿科学[M].北京.人民卫生出版社,2012.1678~1680.
[4] 杨志萍,张美芳.喜炎平联合阿奇霉素对肺炎患儿炎性反应及免疫功能的影响[J].河北医药,2015,(19):2932~2934.
[5] 陈玲,覃军,胡荆江.哌拉西林舒巴坦联合阿奇霉素治疗儿童支原体肺炎的临床疗效及其对血清炎性因子水平的影响[J].实用心脑肺血管病杂志,2016,24(3):98~101.
[6] 龚庆华,李桦,杨涛毅.美洛西林联合阿奇霉素治疗小儿肺炎链球菌肺炎的临床疗效分析[J].实用医院临床杂志,2017,14(2):98~100.
[7] Teramoto S,Yoshida K,Hizawa N.Update on the pathogenesis and management of pneumonia in the elderly-roles of aspiration pneumonia[J].Respir Investig,2015,53(5):178~184.
[8] 杨立新.红霉素联合阿奇霉素序贯疗法与单用阿奇霉素治疗小儿支原体肺炎的效果比较[J].中国医药导报,2016,13(18):173~176.
[9] 郭敏,李奎臣,刘建云,等.肺炎支原体肺炎患儿不同疗程阿奇霉素的应用效果研究[J].中华医院感染学杂志,2016,26(8):1882~1883,1889.
[10] 王丹英,章哲.阿奇霉素不同疗程治疗小儿肺炎支原体肺炎的疗效比较[J].中国基层医药,2015,(24):3736~3738,3739.
[11] Self W H,Williams D J,Zhu Y,et al.Respiratory viral detection in children and adults:comparing asymptomatic controls and patients with community-acquired pneumonia[J].Infect Dis,2016,213(4):584~591.
[12] 吴晓霞,沈珏,张玉平.阿奇霉素治疗小儿支原体属感染肺炎的疗效与安全性观察[J].中华医院感染学杂志,2013,23(23):5798~5800.
[13] 楚加元,许洲.阿奇霉素序贯疗法用于儿童支原体肺炎的临床观察[J].中国药房,2016,27(18):2521~2523.
[14] 陈嘉慧,印根权,余嘉璐,等.红霉素与阿奇霉素治疗小儿肺炎支原体肺炎的临床研究[J].中国临床药理学杂志,2015,(8):587~589.
[15] 万华,李春华,赵年,等.阿奇霉素联合热毒宁注射液治疗肺炎支原体感染患儿的临床观察[J].中国药房,2015,(18):2468~2470.
[16] 叶军.阿奇霉素序贯疗法对支原体肺炎患儿炎性因子及体液免疫功能的影响[J].中国基层医药,2015,(21):3286~3288.
[17] Macdonald B A,Chakravarthy K V,Davidson B A,et al.Halothane modulates the type I interferon response to influenza and minimizes the risk of secondary bacterial pneumonia through maintenance ofneutrophil recruitment in an animal Model[J].Anesthesiology,2015,123(3):590~602.
[18] 于艳艳,赵德育,庄焕自,等.阿奇霉素在支原体感染后气道炎症中的抗炎作用[J].临床儿科杂志,2012,30(2):179~182.